Clinical Trial Update: A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase II clinical trial of Linperlisib (YY-20394) in relapsed or refractory peripheral T/NK cell lymphoma is reported as a Phase 2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Nk Cell Lymphoma

Drugs mentioned

• Linperlisib (linperlisib)

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Peripheral T/NK Cell Lymphoma (R/R PTCL) | Phase 2 | Status: UNKNOWN